Updated:
FDA Classifies Cervical Cytology AI Imaging as Class II
A Nov. 5, 2026 final rule puts AI-assisted digital Pap slide imaging in Class II. What its special controls mean for hospital buyers.
When a vendor says an AI tool is “FDA authorized,” the next question is what the FDA actually required. A final rule published on November 5, 2026 gives a concrete example. It sets the rules for a type of AI-assisted device used to review Pap test slides. This post summarizes the rule for administrators and nursing leaders. It is general information, not legal advice.
What the rule does
The FDA published a final rule (docket FDA-2026-N-12384) classifying the “digital cervical cytology slide imaging system with artificial intelligence algorithm” as Class II, which means it is subject to special controls. The rule is codified at 21 CFR 864.3900. The device is a prescription in vitro diagnostic system that creates, displays, and manages digital images of Pap test slides. Its AI algorithm flags areas that may be clinically significant, and the output helps a trained user reach a cytology diagnosis. The order took effect November 5, 2026, and the classification is stated to apply as of January 31, 2024.
The rule did not exempt these devices from premarket notification. A maker still needs to submit a 510(k) before marketing a device of this type.
What the special controls cover
The rule lists required labeling and testing. In plain terms:
- Labeling must describe intended use, the specimen types, how AI results are shown, and who the intended users are. It must include step-by-step review instructions, recommended user training, performance data, and limits, such as the need to review all flagged areas before diagnosing and to use the tool alongside standard care and clinical judgment. Cybersecurity, including for remote review, is also addressed.
- Testing must cover each hardware part (for example the scanner and display) and system performance. Studies must show results hold across scanners, operators, and sites, and that reading digital images is non-inferior to a standard microscope, with and without AI. Screening time data and human factors testing are required.
Why this matters to buyers
Digital pathology and cytology projects involve scanners, storage, and workflow changes, not only software. These controls give buyers a checklist for vendor conversations: ask which labeled user training is required, what workload limits the labeling recommends, and how the system fits your quality control process. Whether a particular product has cleared review is something to confirm directly with the vendor and your compliance team.
Key takeaways
- A November 5, 2026 final rule classifies AI-assisted digital cervical cytology slide imaging systems as Class II with special controls (21 CFR 864.3900).
- Devices of this type still need a 510(k) before marketing.
- Required labeling and testing include user training, workload limits, and non-inferiority to a standard microscope.
- Use the rule’s list as a starting point for vendor questions; confirm any specific product’s status with the vendor and compliance staff.
Source: Federal Register, document 2026-22593
This site’s content is for general information, research, and education. It does not replace medical diagnosis or advice for any specific patient, and it is not legal advice.